Winner of BioNewsRound Award

RNS Number : 7215W

Oncimmune Holdings PLC

12 December 2019

 

12 December 2019

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Winner of BioNewsRound Award by One Nucleus

Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, is pleased to announce it has received the BioNewsRound Award by One Nucleus which identifies life science companies that have announced exciting developments for patients and the sector over the past year.

The award, which recognises the ground-breaking potential of Oncimmune's EarlyCDT^® Lung test and its use in the Early Detection of Cancer of the Lung Scotland ("ECLS") trial, was presented at Genesis 2019.

-Ends-

For further information:

Oncimmune Holdings plc

Matthew Hall, Chief Financial Officer

[e-mail]

Cléa Rosenfeld, Head of Investor Relations

[e-mail]  

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both autoimmune disease and immuno-oncology. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune's tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT^® Liver. To date, over 155,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled study for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as an office in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT Lung?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit www.oncimmune.com.

 

END

 

 

NRAGGGWUPUPBGCP